Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

被引：20

作者：

Loibl, Sibylle ^{[1
,2
]}

Huang, Chiun-Sheng ^{[3
,4
]}

Mano, Max S. ^{[5
]}

Mamounas, Eleftherios P. ^{[6
,7
]}

Geyer, Charles E. ^{[8
,9
]}

Untch, Michael ^{[10
,11
]}

Thery, Jean-Christophe ^{[12
]}

Schwaner, Ingo

Limentani, Steven ^{[13
]}

Loman, Niklas ^{[14
]}

Lubbe, Kristina ^{[15
]}

Chang, Jenny C. ^{[16
]}

Hatschek, Thomas ^{[17
]}

Tesarowski, David ^{[18
]}

Song, Chunyan ^{[18
]}

de Haas, Sanne Lysbet ^{[19
]}

Boulet, Thomas ^{[19
]}

Lambertini, Chiara ^{[19
]}

Wolmark, Norman ^{[8
,20
]}

机构：

[1] GBG, Neu Isenburg, Germany

[2] Ctr Haematol & Oncol Bethanien, Frankfurt, Germany

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[5] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[6] NSABP Fdn, Orlando, FL USA

[7] Orlando Hlth Canc Inst, Orlando, FL USA

[8] NSABP Fdn, Pittsburgh, PA USA

[9] Univ Pittsburgh, Hillman Canc Ctr, Pittsburgh, PA USA

[10] AGO B, Berlin, Germany

[11] HELIOS Klinikum Berlin Buch, Berlin, Germany

[12] Ctr Henri Becquerel, Canc Ctr, Rouen, France

[13] Atrium Hlth, Charlotte, NC USA

[14] Skane Univ Hosp, Lund, Sweden

[15] Diakovere Henrietten Stift, Hannover, Germany

[16] Houston Methodist Canc Ctr, Houston, TX USA

[17] Karolinska Univ Hosp, Solna, Sweden

[18] Genentech Inc, San Francisco, CA 94080 USA

[19] F Hoffmann La Roche Ltd, Basel, Switzerland

[20] Univ Pittsburgh, Pittsburgh, PA USA

来源：

NPJ BREAST CANCER | 2022年 / 8卷 / 01期

关键词：

NEOADJUVANT CHEMOTHERAPY; HER2; PROGNOSIS;

D O I：

10.1038/s41523-022-00477-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.

引用

页数：6

共 50 条

[11] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Verma, Sunil
Miles, David
Gianni, Luca
Krop, Ian E.
Welslau, Manfred
Baselga, Jose
Pegram, Mark
Oh, Do-Youn
Dieras, Veronique
Guardino, Ellie
Fang, Liang
Lu, Michael W.
Olsen, Steven
Blackwell, Kim
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791
[12] A COST-EFFECTIVESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN PORTUGAL
Silva Miguel, L.
Pinheiro, B.
Lopes, R.
Revil, C.
Monteiro, I
Borges, M.
VALUE IN HEALTH, 2022, 25 (01) : S69 - S70
[13] Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
Mano, Max S.
Loibl, Sibylle
Mamounas, Eleftherios P.
von Minckwitz, Gunter
Huang, Chiun-Sheng
Untch, Michael
Wolmark, Norman
Wapnir, Irene L.
Yang, Youngsen
Conlin, Alison K.
Kuemmel, Sherko
Saghatchian, Mahasti
DiGiovanna, Michael P.
Strunk, Claudia
Zimovjanova, Martina
Song, Chunyan
Liu, Haying
Tesarowski, David
Blotner, Steven
Lam, Lisa H.
Smitt, Melanie
Geyer, Charles E., Jr.
CANCER RESEARCH, 2020, 80 (04)
[14] Trastuzumab improves the prognosis in HER2-positive when compared with HER2-negative patients. Trastuzumab plus vinorelbine in HER2-positive versus vinorelbine alone in HER2-negative metastatic breast cancer patients
Papaldo, P
Fabi, A
Nardoni, C
Pino, S
Ferretti, G
Carlini, P
Mottolese, M
Cianciulli, AM
Alimonti, A
Sperduti, I
Di Cosimo, S
Cognetti, F
BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S72 - S72
[15] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, Dennis
Eiermann, Wolfgang
Robert, Nicholas
Pienkowski, Tadeusz
Martin, Miguel
Press, Michael
Mackey, John
Glaspy, John
Chan, Arlene
Pawlicki, Marek
Tamas Pinter
Valero, Vicente
Liu, Mei-Ching
Sauter, Guido
von Minckwitz, Gunter
Visco, Frances
Bee, Valerie
Buyse, Marc
Bendahmane, Belguendouz
Tabah-Fisch, Isabelle
Lindsay, Mary-Ann
Riva, Alessandro
Crown, John
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
[16] Adjuvant trastuzumab for HER2-positive breast cancer
Spicer, J
Harries, M
Ellis, P
LANCET, 2005, 366 (9486): : 634 - 634
[17] Improved Prognosis by Trastuzumab of Women With HER2-Positive Breast Cancer Compared With Those With HER2-Negative Disease
Ferretti, Gianluigi
Fabi, Alessandra
Felici, Alessandra
Papaldo, Paola
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : E337 - E337
[18] Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
Oostra, Drew R.
Macrae, Erin R.
BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 103 - 113
[19] HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
Qin, Tao
Yuan, Zhongyu
Peng, Roujun
Bai, Bing
Shi, Yanxia
Teng, Xiaoyu
Liu, Donggeng
Wang, Shusen
ONCOTARGETS AND THERAPY, 2013, 6 : 341 - 347
[20] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
Haddley, K.
DRUGS OF TODAY, 2013, 49 (11) : 701 - 715

← 1 2 3 4 5 →